CARLA GONCALVES SCHAHIN SAAD
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
75 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 75
conferenceObject Behcet's Disease Activity: An Important Factor For Immunogenicity Of Unadjuvanted Influenza A/H1N1 Vaccine(2013) PRADO, Leandro L.; SAAD, Carla G. S.; MORAES, Julio C. B.; RIBEIRO, Ana Cristina Medeiros; AIKAWA, Nadia E.; SILVA, Clovis A.; SCHAINBERG, Claudia G.; SAMPAIO-BARROS, Percival D.; PRECIOSO, Alexander R.; ISHIDA, Maria A.; BONFA, Eloisa; GONCALVES, CelioconferenceObject OBSERVATIONAL STUDY OF SWITCHING ANTI-TNF AGENTS IN ANKYLOSING SPONDYLITIS: EFFECTIVENESS AND PREDICTORS(2014) SAAD, C. G. S.; SHIMABUCO, A. Y.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C.; BONFA, E.conferenceObject Latent Tuberculosis Screening and Treatment In Ankylosing Spondylitis Patients Eligible For Anti-TNF Therapy In Endemic Area(2013) MIOSSI, Renata; BONFIGLIOLI, Karina Rossi; SAAD, Carla G. S.; RIBEIRO, Ana Cristina; MORAES, Julio C. B.; BONFA, Eloisa- HIGH RATES OF WORK DISABILITY IN PATIENTS WITH PSORIATIC ARTHRITIS(2015) GASPARI, C. N. De; GOLDEINSTEIN-SCHAINBERG, C.; PRETTI, F. Z.; SILVA, T. C. P.; GONCALVES, C. R.; SAMPAIO-BARROS, P. D.; SAAD, C. G. S.; MORAES, J. C. B.
conferenceObject PREDICTORS OF MORTALITY IN RA PATIENTS BEFORE THE ADVENT OF BIOLOGIC THERAPY(2018) ROSARIO, D. C.; BULHOES, C. N.; TOLEDO, R. P.; BONGLIOLI, K.; RIBEIRO, A. C. M.; MORAES, J. C. B.; SAAD, C. G. S.; SILVA, C. A.; BONFA, E.; AIKAWA, N. E.conferenceObject EFFECT OF LONG-TERM TNF BLOCKAGE ON LIPID PROFILE IN ANKYLOSING SPONDYLITIS PATIENTS(2012) MORAES, J. C.; SOUZA, F. H. C.; RIBEIRO, A. C. D. M.; SAAD, C. G. S.; CALICH, A. L.; SILVA, C. A.; BONFA, E.- Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases(2011) SAAD, Carla G. S.; BORBA, Eduardo F.; AIKAWA, Nadia E.; SILVA, Clovis A.; PEREIRA, Rosa M. R.; CALICH, Ana Luisa; MORAES, Julio C. B.; RIBEIRO, Ana C. M.; VIANA, Vilma S. T.; PASOTO, Sandra G.; CARVALHO, Jozelio F.; FRANCA, Ivan L. A.; GUEDES, Lissiane K. N.; SHINJO, Samuel K.; SAMPAIO-BARROS, Percival D.; CALEIRO, Maria T.; GONCALVES, Celio R.; FULLER, Ricardo; LEVY-NETO, Mauricio; TIMENETSKY, Maria do Carmo S.; PRECIOSO, Alexander R.; BONFA, EloisaBackground Despite the WHO recommendation that the 2010-2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune rheumatic disease (ARD) population. Methods 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic arthritis (PsA), Behcet's disease (BD), mixed connective tissue disease, primary antiphospholipid syndrome (PAPS), dermatomyositis (DM), primary Sjogren's syndrome, Takayasu's arteritis, polymyositis and Granulomatosis with polyangiitis (Wegener's) (GPA)) and 234 healthy controls were vaccinated with a non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu. Subjects were evaluated before vaccination and 21 days post-vaccination. The percentage of seroprotection, seroconversion and the factor increase in geometric mean titre (GMT) were calculated. Results After immunisation, seroprotection rates (68.5% vs 82.9% p < 0.0001), seroconversion rates (63.4% vs 76.9%, p < 0.001) and the factor increase in GMT (8.9 vs 13.2 p < 0.0001) were significantly lower in ARD than controls. Analysis of specific diseases revealed that seroprotection significantly reduced in SLE (p < 0.0001), RA (p < 0.0001), PsA (p=0.0006), AS (p=0.04), BD (p=0.04) and DM (p=0.04) patients than controls. The seroconversion rates in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p=0.0006) patients and the increase in GMTs in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p < 0.0001) patients were also reduced compared with controls. Moderate and severe side effects were not reported. Conclusions The novel recognition of a diverse vaccine immunogenicity profile in distinct ARDs supports the notion that a booster dose may be recommended for diseases with suboptimal immune responses. This large study also settles the issue of vaccine safety. (ClinicalTrials.gov #NCT01151644)
conferenceObject A CROSS-SECTIONAL EVALUATION OF A BRAZILIAN SPONDYLOARTHRITIS SINGLE-CENTER TERTIARY COHORT: CLINICAL AND TREATMENT DATA(2018) SHIMABUCO, A.; MORAES, J. C. B. de; SAMPAIO-BARROS, P.; GOLDENSTEIN-SCHAINBERG, C.; GONCALVES, C. R.; SAAD, C. G. S.conferenceObject INFLUENCE OF SULFASALAZINE COMEDICATION IN SWITCHING AND RESPONSE TO ANTI-TUMORAL NECROSIS FACTOR IN ANKYLOSING SPONDYLITIS(2016) SHIMABUCO, A. Y.; GONCALVES, C. R.; MORAES, J. C. B.; WAISBERG, M. G.; RIBEIRO, A. C. M.; SAMPAIO-BARROS, P. D.; GOLDENSTEIN-SCHAINBERG, C.; BONFA, E.; SAAD, C. G. S.conferenceObject Metabolic Syndrome in Patients with Psoriatic Arthritis Is Associated to Peripheral Disease Activity(2015) GASPARI, Camilla De; MORAES, Julio C. B.; SAMPAIO-BARROS, Percival D.; GONCALVES, Celio R.; SAAD, Carla G. S.; GOLDENSTEIN-SCHAINBERG, Claudia